Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Oncology Asia Chief Jorge Puente On Asia’s Role In Xalkori’s Success: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Jorge Puente, Pfizer’s regional president, Asia Pacific and Canada, Oncology BU, discusses the origins of the NSCLC therapy Xalkori, and how Asian clinical trials helped turbo-charge development of the oral, small molecule inhibitor of c-Met and ALK.

Advertisement

Related Content

Synchronized Regulation: Tandem Approvals Of Xalkori, Diagnostic Required Considerable Coordination
Pfizer’s Crizotinib Eases Past FDA With Targeted Population

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC080801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel